Stellar gets European nod for NeoVisc single dose

Stellar Pharmaceuticals (OTCQB, OTCBB:SLXCF) has received CE Mark for its NeoVisc single dose viscosupplement therapy, denoting conformity with European standards for safety and allowing the company to market both its NeoVisc triple dose and its single dose products in the European Union. “This approval is a significant milestone in Stellar’s global licensing strategy, as osteoarthritis [...]

Stellar taps familiar face as advisory consultant for U.S. market

Stellar Pharmaceuticals (OTCQB:SLXCF) has engaged the services of Advisory Associates (AAI) as an advisory consultant to locate leads and assist in negotiating a license deal for the company’s products, NeoVisc and Uracyst for the U.S. market. “I am pleased that we were able to enter into this agreement with AAI given its experience and proven [...]

Stellar retains business development consultant

Stellar Pharmaceuticals (OTCQB:SLXCF) has engaged P-A-K Limited’s founder, Paul Kirkconnell, as a consultant on business development matters. Under the terms of the agreement, Mr. Kirkconnell will act as Stellar’s senior strategic advisor and will provide advice and assistance to the company regarding the identification of business opportunities, assisting in the negotiation of contractual relationships and [...]

OTC quotation leaves many dazed and confused

We’ve noticed a growing buzz on the Street about a sudden lack of quotation activity on the OTCBB, with a lot of company quotations moving to the OTCQB.  Developed by the OTC Markets Group, OTCQB is a competing inter-market quotation system with OTCBB.  In the past week, it seems that certain market makers have stopped [...]

Riehl retires as CEO of Stellar Pharmaceuticals

Peter Riehl has retired as CEO, president and a director of Stellar Pharmaceuticals (OTCBB: SLXCF), effective yesterday. Arnold Tenney, who has been chairman of Stellar since 2005, will serve as the interim CEO until a permanent replacement for Mr. Riehl is retained. Stellar markets direct in Canada and in countries around the world through out-licensing [...]

Korea clears Stellar’s Uracyst

The Korean Food and Drug Administration has approved Stellar Pharmaceuticals’ (OTCBB:SLXCF) Uracyst for the treatment of interstitial cystitis/painful bladder syndrome. Uracyst will be distributed in South Korea by Stellar’s licensee in that market, Jeilmedix Pharmaceutical, which has a major focus in urology, the primary target market for Uracyst. Stellar expects to deliver the initial commercial order to [...]

Stellar analyzing high placebo response rate in pilot study

Stellar Pharmaceuticals (OTCBB:SLXCF) believes that an “anomalously high placebo response rate may be a possible reason for the primary efficacy endpoints … not having been met” in Watson Pharma’s (NYSE:WPI) pilot study of Stellar’s Uracyst drug for the treatment of interstitial cystitis/painful bladder syndrome (IC/PBS) in the U.S. The company said it plans to continue [...]

Stellar in non-brokered private placement

Stellar Pharmaceuticals (OTCBB: SLXCF) is arranging a non-brokered private placement, consisting of up to one million units at a price of $1 (U.S.) a unit. Each unit will consist of one common share and one-half of a Series 1 warrant, one-half of a Series 2 warrant and one-half of a Series 3 warrant. During the [...]

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

Stellar signs Uracyst distributor in Spain

Stellar Pharmaceuticals (OTCBB: SLXCF) has signed a license agreement with Laboratorios Inibsa S.A. for the sale and distribution in Spain of one of its lead products, Uracyst, for the treatment of interstitial cystitis/painful bladder syndrome. Uracyst already has CE mark approval in Europe and Inibsa is expected to launch the drug in the fourth quarter [...]

Next Page »